From the Centre for Molecular Biotechnology,
Queensland University of Technology, Gardens Point, Brisbane 4000, Australia, § The Scripps Research Institute, La Jolla,
California 92037, and the ¶ Cellular Oncology Laboratory,
University of Queensland and the Queensland Institute of Medical
Research, Brisbane 4029, Australia
Cell surface proteolysis has emerged as an
important mechanism for the generation of biologically active proteins
that mediate a diverse range of cellular functions. The proteolytic
activities of membrane-anchored proteins, such as
ADAMs1 (1) and MT-MMPs (2),
are thought to play central roles in cell surface-activating events. In
contrast, most of the members of the serine protease family, one of the
oldest characterized and largest multigene proteolytic families, are
either secreted enzymes or sequestered in cytoplasmic storage
organelles awaiting signal-regulated release. These serine proteases
have well characterized roles in diverse cellular activities, including
blood coagulation, wound healing, digestion, and immune responses, as
well as tumor invasion and metastasis. However, during the last few
years there has been an explosion in the identification of
transmembrane proteins containing C-terminal extracellular serine
protease domains. These enzymes are ideally positioned to interact with
other proteins on the cell surface as well as soluble proteins, matrix
components, and proteins on adjacent cells. In addition, these
membrane-spanning proteases have cytoplasmic N-terminal domains,
suggesting possible functions in intracellular signal transduction.
This review delineates for the first time this emerging class of cell
surface proteolytic enzymes, the type II transmembrane serine proteases
(TTSPs), to highlight their structural features, expression profiles,
and possible roles in mediating cell surface proteolytic events.
In mammals the TTSPs currently consist of 17 members (Table
I), of which seven are found in man.
Enteropeptidase (also known as enterokinase) (3), because of its
essential role in the processing of digestive proteases, was the first
member of this group to be discovered nearly a century ago. The other
more recently identified members include hepsin (4), human airway
trypsin-like protease (HAT) (5), corin (6), MT-SP1 (7) (also known as
matriptase (8)), TMPRSS2 (9), and most recently
TMPRSS42 (10). The only
nonmammalian TTSP identified to date is the Drosophila
protease stubble-stubbloid (st-sb) (11). Mammalian orthologues have
been reported for enteropeptidase (mouse (12), rat (13), cow (14), and
pig (15)), hepsin (mouse (16) and rat (17)), corin (mouse, also known
as LRP4 (18)), MT-SP1 (mouse, also known as epithin (19)), and
TMPRSS2 (mouse, also known as epitheliasin (20)) (Table
I). The TTSPs share a number of common structural features including
(i) a proteolytic domain, (ii) a transmembrane domain, (iii) a short
cytoplasmic domain, and (iv) a variable length stem region containing
modular structural domains, which links the transmembrane and catalytic
domains (Fig. 1). It is this unique
combination of domains that suggests novel roles for the TTSPs at the
cell surface.
INTRODUCTION
TOP
INTRODUCTION
Structural Features of TTSPs
Tissue Expression of TTSPs
Biochemical Data and...
Analogous Membrane-associated...
Concluding Remarks
REFERENCES
Structural Features of TTSPs
TOP
INTRODUCTION
Structural Features of TTSPs
Tissue Expression of TTSPs
Biochemical Data and...
Analogous Membrane-associated...
Concluding Remarks
REFERENCES
Summary of type II transmembrane serine proteases
View larger version (37K):
[in a new window]
Fig. 1.
Type II transmembrane serine protease domain
structure. Structures, listed by length, are of the seven human
TTSPs and the Drosophila TTSP st-sb. The amino acid
(aa) sequence of each protein was scanned using the
ProfileScan algorithm to confirm the presence of each domain.
Numbers delineate the location of each domain.
Proteolytic Domains-- As is the case for the wider family of enzymes of the chymotrypsin (S1) fold,3 the proteolytic domains of the TTSPs share a high degree of amino acid sequence identity. In particular, the histidine, aspartate, and serine residues necessary for catalytic activity are present in highly conserved motifs. TTSPs are synthesized as single chain zymogens and are likely activated by cleavage following an arginine or lysine present in a highly conserved activation motif. Based on the predicted presence of a conserved disulfide bond linking the pro- and catalytic domains (Fig. 1), the TTSPs are likely to remain membrane-bound following activation. However, the isolation of soluble forms of enteropeptidase (21, 22), HAT (23), and MT-SP1 (24) suggests that the extracellular domains of at least some of the TTSPs may also be shed from the cell surface. Other cysteine residues conserved among the TTSPs include six cysteines predicted to form three intraprotease domain disulfide bonds. Enteropeptidase and hepsin each have one and corin has two additional predicted disulfide linkages within the catalytic domain. The presence of an aspartate six residues before the catalytic serine, which in the activated TTSP would be positioned at the bottom of the S1 substrate binding pocket, is indicative that all of the TTSPs have preference for substrates containing an arginine or lysine in the P1 amino acid position (S1 and P1 designations are described (25)). The cleavage specificities and candidate physiological substrates for some of the TTSPs have been elucidated. The predicted cleavage specificity following basic amino acids indicates that the TTSPs are likely to have a degree of autocatalytic activity. Indeed truncated mouse hepsin lacking cytoplasmic and transmembrane domains (16) and the human MT-SP1 proteolytic domain (7) are capable of autoactivation. In contrast, bovine enteropeptidase has extremely low autocatalytic activity (26). Interestingly, the proteolytic domain of bovine enteropeptidase has an additional role in the targeting of enteropeptidase to the apical membrane of enterocytes (27).
Transmembrane Domains-- Each of the TTSPs contains a hydrophobic domain near the N terminus. This domain is predicted to span the plasma membrane in such a way that the proteolytic domain lies extracellularly, presumably to localize TTSP proteolytic activity in close proximity to target substrates and/or to permit regulated release of the protein from the cell surface. Cell surface localization has been experimentally demonstrated for enteropeptidase, hepsin (28, 29), MT-SP1 (30, 31), TMPRSS2 (20), and TMPRSS3 (10).
Cytoplasmic Domains-- The cytoplasmic domains of the TTSPs (Fig. 1) range in length from 12 amino acids for HAT to 112 amino acids for murine corin. Whether these domains have the potential to support interactions with cytoskeletal components and signaling molecules is not yet known. However, a number of the TTSPs including corin, MT-SP1, st-sb, and TMPRSS2 contain consensus phosphorylation sites for either or both of protein kinase C and casein kinase II. In addition, based on the cellular sorting of other integral membrane proteins (32) it is likely that the cytoplasmic and transmembrane domains also contribute to the targeting of the TTSPs to a particular cell surface in polarized cells.
Stem Regions-- The stem regions of the TTSPs contain as many as 11 structural domains that may serve as regulatory and/or binding domains (Fig. 1). These include low density lipoprotein (LDL) receptor class A domains, Group A scavenger receptor (SR) domains, frizzled domains, Cls/Clr, urchin embryonic growth factor and bone morphogenic protein 1 (CUB) domains, sea urchin sperm protein, enterokinase, agrin (SEA) domains, a meprin, A5 antigen, and receptor protein phosphatase µ (MAM) domain, and a disulfide knotted domain. Hepsin is the only TTSP that does not possess an identified structural domain within its stem region. Although functional roles for individual stem region domains have not been demonstrated, the stem region of bovine enteropeptidase has been shown to be required for efficient cleavage of its physiological substrate trypsinogen (26). In addition, the N terminus of the stem region of this protein is required for delivery of enteropeptidase to the apical surface of polarized Madin-Darby canine kidney cells (27).
The most common stem region structural domain is the LDL receptor class A domain: corin contains eight, MT-SP1 four, enteropeptidase two, and TMPRSS2 and TMPRSS4 one each (Fig. 1). Although the function of these domains in the TTSPs has not been demonstrated, in other proteins they bind Ca2+ ions and mediate the internalization of macromolecules including serine protease·inhibitor complexes and lipoproteins (33-35). In addition, although LDL receptor domains also function in the uptake of LDLs, increased LDL uptake could not be demonstrated following expression of murine corin in COS cells (18).
Six other structural domains that are thought to be involved in
protein-protein interactions or protein-ligand interactions are found
in various TTSPs. SR domains (36) are present in corin, enteropeptidase, TMPRSS2, and TMPRSS3; frizzled domains (37) are
present in corin; CUB domains (38) are present in enteropeptidase and
MT-SP1; SEA domains (39) are present in HAT and enteropeptidase; a MAM
domain (40) is present in enteropeptidase; and a disulfide knotted
domain (41) is present in st-sb (Fig. 1). In addition to these
structural domains, human and mouse MT-SP1s possess a conserved RGD
motif (42) present in the first CUB domain. Interestingly, truncated
human MT-SP1 lacking cytoplasmic and transmembrane domains remains
bound to the cell surface of COS cells (31). Binding may be mediated
via an interaction between the MT-SP1 RGD motif and an integrin protein
or another cell surface protein. Alternatively, the mode of attachment
could be via a direct link such as a hydrocarbon chain.
![]() |
Tissue Expression of TTSPs |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although a few of the TTSPs are expressed across several tissue
and cell types, in general these enzymes demonstrate relatively restricted expression patterns, indicating that they may have tissue-specific functions (Table I). Enteropeptidase shows a very
narrow expression pattern, being restricted in normal tissues to
enterocytes of the proximal small intestine (12). Corin expression is
also quite specific, with corin mRNA highly expressed in human heart (6) and corin protein expression localized to cardiac myocytes
(43). HAT is predominantly expressed in trachea (5, 23). Human TMPRSS2
expression is predominantly associated with prostate (9,
44).4 Hepsin, originally
identified from liver, is highly expressed in fetal liver and kidney
(45). Hepsin mRNA has been reported to be overexpressed by ovarian
tumors (46), and protein expression has been localized to tumor cell
membranes in renal cell carcinoma (29). TMPRSS4 has only recently
been characterized and was identified as a consequence of its strong
up-regulation in pancreatic tumors (10). While TMPRSS4 was not detected
in normal pancreas, very low level TMPRSS4 mRNA expression was
detected in tissues of the gastrointestinal tract and in some tissues
of the urogenital tract (10). MT-SP1 was originally identified from
a human breast cancer line (30) but shows the broadest pattern of
expression of the TTSPs being detected in a wide range of both human
(7) and murine tissues (19).
![]() |
Biochemical Data and Pathophysiological Roles |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The majority of the TTSPs have been identified relatively recently and consequently have not been extensively characterized. Enteropeptidase is somewhat of an exception. Although the enzymatic activity ascribed to enteropeptidase was first identified almost a century ago (47) it has been only recently that the complete amino acid sequence was described (3). Enteropeptidase functions near the apex of the digestive enzymatic cascade activating the digestive protease trypsinogen to trypsin, which subsequently activates other enzymes including chymotrypsinogen, proelastase, prolipases, and procarboxypeptidases. Enteropeptidase possesses extremely low autocatalytic activity, and it has been proposed that the serine protease duodenase, secreted by duodenal epitheliocytes, may be its physiological activator (48). Active enteropeptidase consists of heavy and light chains that are extensively glycosylated (27, 49). It has recently been reported that physiological concentrations of pancreatic trypsin activate protease-activated receptor (PAR) 2 at the apical membrane of enterocytes (50). PAR2 is a member of the PAR family of signal-transducing, G protein-coupled, plasma membrane-spanning receptors, which are activated by the proteolytic action of select serine proteases (51, 52). These data and the observation that an exosite in the heavy chain of enteropeptidase is required for efficient recognition of trypsinogen (26) suggest that enteropeptidase may play a role in facilitating trypsin-mediated PAR2 activation on enterocytes. Thus enteropeptidase may localize trypsinogen/trypsin at the membrane of enterocytes, initiating a limited proteolytic cascade at the cell surface in close proximity to the trypsin cleavage target PAR2, thereby facilitating receptor activation and signal transduction.
Hepsin is a glycoprotein originally cloned from human liver and
hepatoma cell lines and, more recently, implicated in mammalian cell
growth and morphology (53), tumor progression (28), and developmental
processes, such as blastocyst hatching (16). The importance of hepsin
in vivo, however, remains unclear as homozygous hepsin null
mice are phenotypically normal (54). An as yet unexplained phenotype of
the hepsin /
mice is a 2-fold higher serum concentration of
bone-derived alkaline phosphatase compared with wild type mice (55).
The human airway TTSP, HAT, was originally purified as a soluble protein from the sputum of patients with chronic airway diseases. Full-length HAT is synthesized, translocated to the cell surface where it is processed to a soluble form, and then released from tracheal serous glands as part of the host immune defense system (5).
Significantly, the human heart TTSP, corin, is an in vitro activator of pro-atrial natriuretic peptide (ANP), a cardiac hormone essential for the regulation of blood pressure (56), suggesting that corin is the long sought pro-ANP convertase. This proteolytic cleavage is critical for the regulation of ANP activity (57); thus, corin may well prove to be an important factor in the regulation of major cardiovascular diseases. Dysfunctional corin was proposed to be a candidate for the rare congenital heart disease, total anomalous pulmonary venous return (TAPVR), as the corin gene colocalizes to the TAPVR locus on human chromosome 4p12-13 (6). In addition to heart, murine corin is expressed by chondrocytes in a differentiation stage-specific manner during mouse development, suggesting that this protease may play a role during chondrocyte differentiation/bone formation (6). However, while human and murine corin share high homology, common structural features, expression profiles, and syntenic chromosomal locations, these proteases are variant in the lengths of their cytoplasmic domains (45 residues in human and 112 in mouse) and show no conservation in amino acid sequence in this domain. This may indicate that murine and human corin have different but perhaps overlapping species-specific roles, or alternatively the cytoplasmic domain is not essential for corin functions.
In other significant recent experiments it has been shown that MT-SP1 may be involved in initiating signaling and proteolytic cascades via the activation of the cell surface-associated proteins PAR2 and pro-uPA (31). Interestingly, MT-SP1 from breast cancer cells is detected largely as an uncomplexed protein, whereas in milk it is present mainly as a complex with the Kunitz-type serine protease inhibitor hepatocyte growth factor inhibitor-1 (24). It will be important to identify the inhibitor binding domains of MT-SP1 and the function of the protease·inhibitor complex.
TMPRSS2 and TMPRSS4 have been identified through association with cancer. TMPRSS2 is thought to play a role in epithelial cell biology, and its association with prostate carcinogenesis has led to the proposal that it may be a diagnostic or therapeutic target for prostate cancer (44). TMPRSS2 has been proposed to be part of an enzymatic cascade involving the serine proteases prostate-specific antigen and human kallikrein K2 in a manner analogous to the fibrinolytic and blood coagulation cascades (44). TMPRSS4 is overexpressed in pancreatic cancers; however, its functional significance remains unclear (10).
The Drosophila serine protease st-sb is one of a number of
proteases involved in fly morphogenesis (11) and has a proteolytic function in detaching imaginal disks from extracellular matrices. In addition, the phenotype of st-sb mutants has led to speculation that
the encoded protein is involved in outside to inside signal transduction via its cytoplasmic domain, thus resulting in cytoskeletal reorganization and changes in cell shape during morphogenesis (11).
![]() |
Analogous Membrane-associated Proteolytic Systems |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In contrast to the traditional protein catabolic functions of many of the secreted members of the serine protease family and based on the presence of multiple structural domains in the TTSPs, it is tantalizing to speculate that the TTSPs function as key regulators of signaling events at the plasma membrane. Precedents for such functions come from other more well characterized membrane-associated proteolytic systems such as the ADAMs (1), the MT-MMPs (2), and the uPA·uPA receptor system (58).
The ADAMs have recognized and proposed roles in the proteolysis of extracellular matrix (ECM) components and cell surface proteins, in mediating cell adhesion via integrin binding, in cell fusion and signaling via interactions of their cytoplasmic domains, and in RGD-mediated interactions with integrins (59-61). The TTSPs are similarly positioned at the plasma membrane to release ECM components and to proteolytically activate cell surface proteins such as PARs, growth factors, and cytokines, and to interact with cell surface and soluble ligands. In addition, the presence of the cytoplasmic domains indicates that the TTSPs may be capable of interacting with the cytoskeleton and/or with cellular signaling molecules.
The MT-MMPs function in pericellular cascades to activate other MMPs involved in the cleavage of ECM components. The TTSPs may well perform similar functions in activating proteolytic cascades on the plasma membrane. Indeed, this function has been demonstrated for enteropeptidase in the activation of digestive proteases. Moreover, there is increasing evidence for cross-talk between proteolytic systems. The uPA·uPA receptor system of cell surface-localized proteolytic activity has a recognized role in the initial stage of MMP activation (62), and other serine proteases are also capable of in vitro MMP activation (63, 64). The TTSPs could play a direct role in MMP activation or an indirect role in localizing and activating other serine proteases more directly associated with MMP activation. The activation of uPA by MT-SP1 (31) and subsequent downstream MMP activation could be an example of such cross-talk.
Several other parallels may also be drawn from the uPA·uPA receptor
system. That the TTSPs are directly anchored to the plasma membrane
implies that they have potential to mimic localization of the
uPA·uPAR system to the leading edge of migrating tumor cells (65).
Further, the interaction of the uPA·uPAR system, via a nonproteolytic
mechanism, in mediating cell-cell contacts through association with
integrins may also parallel TTSP properties. Indeed the multidomain
structure of the TTSPs indicates their capacity to interact with
multiple partners and suggests the possibility that these membrane
proteins may form part of a signalosome-like complex, thereby mediating
at the cell surface multiple signaling pathways as is the case for the
uPA·uPAR system (58).
![]() |
Concluding Remarks |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
What is known about the TTSPs is that they function or have
the structural motifs necessary to function as serine proteases. What
can be speculated upon is that their numerous and varied nonproteolytic
domains are likely to mediate interactions with proteolytic substrates
and inhibitors as well as other proteins and ligands. Such interactions
will potentially regulate the proteolytic activity of the catalytic
domain but perhaps may also have functions quite independent of this
domain. Furthermore, given the integral plasma membrane nature of the
TTSPs, it is tempting to speculate that at least some of the TTSPs will
function directly in transducing signals across the plasma membrane, as
has been suggested for the Drosophila TTSP st-sb (11).
There is clearly a need for a greater understanding of the biology and
physiological functions of this group of unique proteases to obtain a
better picture of the dynamics occurring on the cell surface. Because
of the mosaic structure of the TTSPs it will be important to understand
the role of their individual domains as well as the role of each
protein in toto.
![]() |
Note Added in Proof |
---|
Two cDNAs encoding the putative TTSPs Xesp-2 and XMT-SP1 have recently been identified from Xenopus laevis (67).
![]() |
FOOTNOTES |
---|
To whom correspondence should be addressed. Tel.:
617-3362-0312; Fax: 617-3362-0107; E-mail: toniA@qimr.edu.au.
Published, JBC Papers in Press, November 1, 2000, DOI 10.1074/jbc.R000020200
3 Information on the classification and nomenclature of the S1 family of peptidases can be found in the Internet-accessible MEROPS data base.
4 The Northern blot data reported (9) are incorrectly labeled due to inversion of the membranes (Stylianos Antonarakis, personal communication).
2 Originally designated TMPRSS3 (10). The Human Genome Nomenclature Committee-approved symbol TMPRSS3 has been allocated to a predicted TTSP-encoding gene located on chromosome 21q22.3 (66). The amino acid sequence of the TMPRSS3 protein has not been reported.
This minireview will be reprinted in the 2001 Minireviw Compendium, which will be available in December, 2001. This work was supported by the National Health and Medical Research Council of Australia, the Queensland Cancer Fund, and the National Institutes of Health.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: ADAM, a disintegrin-like and metalloproteinase; ANP, atrial natriuretic peptide; CUB, Cls/Clr, urchin embryonic growth factor and bone morphogenetic protein 1; ECM, extracellular matrix; HAT, human airway trypsin-like protease; LDL, low density lipoprotein; MAM, meprin, A5 antigen, and receptor protein phosphatase µ; MT-MMP, membrane-type matrix metalloproteinase; PAI-1, plasminogen activator inhibitor-1; PAR, protease-activated receptor; SEA, sea urchin sperm protein-enterokinase-agrin; SR, Group A scavenger receptor; st-sb, stubble-stubbloid; TAPVR, total anomalous pulmonary venous return; TTSP, type II transmembrane serine protease; uPA, urokinase-type plasminogen activator; uPAR, uPA receptor.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Stone, A. L., Kroeger, M., and Sang, Q. X. (1999) J. Protein Chem. 18, 447-465[CrossRef][Medline] [Order article via Infotrieve] |
2. | Seiki, M. (1999) APMIS 107, 137-143[Medline] [Order article via Infotrieve] |
3. | Kitamoto, Y., Veile, R. A., Donis-Keller, H., and Sadler, J. E. (1995) Biochemistry 34, 4562-4568[Medline] [Order article via Infotrieve] |
4. | Leytus, S. P., Loeb, K. R., Hagen, F. S., Kurachi, K., and Davie, E. W. (1988) Biochemistry 27, 1067-1074[Medline] [Order article via Infotrieve] |
5. |
Yamaoka, K.,
Masuda, K.,
Ogawa, H.,
Takagi, K.,
Umemoto, N.,
and Yasuoka, S.
(1998)
J. Biol. Chem.
273,
11895-11901 |
6. |
Yan, W.,
Sheng, N.,
Seto, M.,
Morser, J.,
and Wu, Q.
(1999)
J. Biol. Chem.
274,
14926-14935 |
7. |
Takeuchi, T.,
Shuman, M. A.,
and Craik, C. S.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
11054-11061 |
8. |
Lin, C.-Y.,
Anders, J.,
Johnson, M.,
Sang, Q. A.,
and Dickson, R. B.
(1999)
J. Biol. Chem.
274,
18231-18236 |
9. | Paoloni-Giacobino, A., Chen, H., Peitsch, M. C., Rossier, C., and Antonarakis, S. E. (1997) Genomics 44, 309-320[CrossRef][Medline] [Order article via Infotrieve] |
10. |
Wallrapp, C.,
Hahnel, S.,
Muller-Pillasch, F.,
Burghardt, B.,
Iwamura, T.,
Ruthenburger, M.,
Lerch, M. M.,
Adler, G.,
and Gress, T. M.
(2000)
Cancer Res.
60,
2602-2606 |
11. | Appel, L. F., Prout, M., Abu-Shumays, R., Hammonds, A., Garbe, J. C., Fristrom, D., and Fristrom, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4937-4941[Abstract] |
12. |
Yuan, X.,
Zheng, X.,
Lu, D.,
Rubin, D. C.,
Pung, C. Y.,
and Sadler, J. E.
(1998)
Am. J. Physiol.
274,
G342-G349 |
13. | Yahagi, N., Ichinose, M., Matsushima, M., Matsubara, Y., Miki, K., Kurokawa, K., Fukamachi, H., Tashiro, K., Shiokawa, K., Kageyama, T., Takahashi, T., Inoue, H., and Takahashi, K. (1996) Biochem. Biophys. Res. Commun. 219, 806-812[CrossRef][Medline] [Order article via Infotrieve] |
14. | Kitamoto, Y., Yuan, X., Wu, Q., McCourt, D. W., and Sadler, J. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7588-7592[Abstract] |
15. |
Matsushima, M.,
Ichinose, M.,
Yahagi, N.,
Kakei, N.,
Tsukada, S.,
Miki, K.,
Kurokawa, K.,
Tashiro, K.,
Shiokawa, K.,
Shinomiya, K.,
Umeyama, H.,
Inoue, H.,
Takahashi, T.,
and Takahashi, H.
(1994)
J. Biol. Chem.
269,
19976-19982 |
16. |
Vu, T. K. H.,
Liu, R. W.,
Haaksma, C. J.,
Tomasek, J. J.,
and Howard, E. W.
(1997)
J. Biol. Chem.
272,
31315-31320 |
17. | Farley, D., Reymond, F., and Nick, H. (1993) Biochim. Biophys. Acta 1173, 350-352[Medline] [Order article via Infotrieve] |
18. | Tomita, Y., Kim, D. H., Magoori, K., Fujino, T., and Yamamoto, T. T. (1998) J. Biochem. (Tokyo) 124, 784-789[Abstract] |
19. | Kim, M. G., Chen, C., Lyu, M. S., Cho, E. G., Park, D., Kozak, C., and Schwartz, R. H. (1999) Immunogenetics 49, 420-428[CrossRef][Medline] [Order article via Infotrieve] |
20. | Jacquinet, E., Rao, N. V., Rao, G. V., and Hoidal, J. R. (2000) FEBS Lett. 468, 93-100[CrossRef][Medline] [Order article via Infotrieve] |
21. | Louvard, D., Maroux, S., Baratti, J., and Desnuelle, P. (1973) Biochim. Biophys. Acta 309, 127-137[Medline] [Order article via Infotrieve] |
22. |
Fonseca, P.,
and Light, A.
(1983)
J. Biol. Chem.
258,
14516-14520 |
23. | Yasuoka, S., Ohnishi, T., Kawano, S., Tsuchihashi, S., Ogawara, M., Masuda, K., Yamaoka, K., Takahashi, M., and Sano, T. (1997) Am. J. Respir. Cell Mol. Biol. 16, 300-308[Abstract] |
24. |
Lin, C.-Y.,
Anders, J.,
Johnson, M.,
and Dickson, R. B.
(1999)
J. Biol. Chem.
274,
18237-18242 |
25. | Schechter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157-162[Medline] [Order article via Infotrieve] |
26. |
Lu, D.,
Yuan, X.,
Zheng, X.,
and Sadler, J. E.
(1997)
J. Biol. Chem.
272,
31293-31300 |
27. |
Zheng, X.,
Lu, D.,
and Sadler, J. E.
(1999)
J. Biol. Chem.
274,
1596-1605 |
28. |
Kazama, Y.,
Hamamoto, T.,
Foster, D. C.,
and Kisiel, W.
(1995)
J. Biol. Chem.
270,
66-72 |
29. | Zacharski, L. R., Ornstein, D. L., Memoli, V. A., Rousseau, S. M., and Kisiel, W. (1998) Thromb. Haemostasis 79, 876-877[Medline] [Order article via Infotrieve] |
30. |
Lin, C.-Y.,
Wang, J. K.,
Torri, J.,
Dou, L.,
Sang, Q. A.,
and Dickson, R. B.
(1997)
J. Biol. Chem.
272,
9147-9152 |
31. |
Takeuchi, T.,
Harris, J.,
Huang, W.,
Yan, K. W.,
Coughlin, S. R.,
and Craik, C. S.
(2000)
J. Biol. Chem.
275,
26333-26342 |
32. |
Keller, P.,
and Simons, K.
(1997)
J. Cell Sci.
110,
3001-3009 |
33. | Brown, M. S., Herz, J., and Goldstein, J. L. (1997) Nature 388, 629-630[CrossRef][Medline] [Order article via Infotrieve] |
34. |
Nykjcer, A.,
Conese, M.,
Christensen, E. I.,
Olson, D.,
Cremona, O.,
Glieman, J.,
and Blasi, F.
(1997)
EMBO J.
16,
2610-2620 |
35. |
Kounnas, M. Z.,
Church, F. C.,
Argraves, W. S.,
and Strickland, D. K.
(1996)
J. Biol. Chem.
271,
6523-6529 |
36. |
Resnick, D.,
Chatterton, J. E.,
Schwartz, K.,
Slayter, H.,
and Krieger, M.
(1996)
J. Biol. Chem.
271,
26924-26930 |
37. |
Cadigan, K. M.,
and Nusse, R.
(1997)
Genes Dev.
11,
3286-3305 |
38. | Bork, P., and Beckmann, G. (1993) J. Mol. Biol. 231, 539-545[CrossRef][Medline] [Order article via Infotrieve] |
39. |
Bork, P.,
and Patthy, L.
(1995)
Protein Sci.
4,
1421-1425 |
40. | Beckmann, G., and Bork, P. (1993) Trends Biochem. Sci. 18, 40-41[CrossRef][Medline] [Order article via Infotrieve] |
41. |
Muta, T.,
Hashimoto, R.,
Miyata, T.,
Nishimura, H.,
Toh, Y.,
and Iwanaga, S.
(1990)
J. Biol. Chem.
265,
22426-22433 |
42. | Hynes, R. O. (1992) Cell 69, 11-25[Medline] [Order article via Infotrieve] |
43. |
Hooper, J. D.,
Scarman, A. L.,
Clarke, B. E.,
Normyle, J. F.,
and Antalis, T. M.
(2000)
Eur. J. Biochem.
267,
6931-6937 |
44. |
Lin, B.,
Ferguson, C.,
White, J. T.,
Wang, S.,
Vessella, R.,
True, L. D.,
Hood, L.,
and Nelson, P. S.
(1999)
Cancer Res.
59,
4180-4184 |
45. |
Tsuji, A.,
Torres-Rosado, A.,
Arai, T.,
Le Beau, M. M.,
Lemons, R. S.,
Chou, S. H.,
and Kurachi, K.
(1991)
J. Biol. Chem.
266,
16948-16953 |
46. | Tanimoto, H., Yan, Y., Clarke, J., Korourian, S., Shigemasa, K., Parmley, T. H., Parham, G. P., and O'Brien, T. J. (1997) Cancer Res. 57, 2884-2887[Abstract] |
47. | Pavlov, I. P. (1902) The Work of the Digestive Glands, 1st Ed., pp. 148-163, translated by W. H. Thompson, Charles Griffin & Co., London |
48. | Zamolodchikova, T. S., Sokolova, E. A., Lu, D., and Sadler, J. E. (2000) FEBS Lett. 466, 295-299[CrossRef][Medline] [Order article via Infotrieve] |
49. | Lu, D., and Sadler, J. E. (1998) in Handbook of Proteolytic Enzymes (Barrett, A. J. , Rawlings, N. D. , and Woessner, J. F., eds) , pp. 50-54, Academic Press Ltd., London |
50. |
Kong, W.,
McConalogue, K.,
Khitin, L. M.,
Hollenberg, M. D.,
Payan, D. G.,
Bohm, S. K.,
and Bunnett, N. W.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8884-8889 |
51. | Dery, O., and Bunnett, N. W. (1999) Biochem. Soc. Trans. 27, 246-254[Medline] [Order article via Infotrieve] |
52. | Hollenberg, M. D. (1999) Trends Pharmacol. Sci. 20, 271-273[CrossRef][Medline] [Order article via Infotrieve] |
53. | Torres-Rosado, A., O'Shea, K. S., Tsuji, A., Chou, S. H., and Kurachi, K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7181-7185[Abstract] |
54. |
Wu, Q., Yu, D.,
Post, J.,
Halks, M. M.,
Sadler, J. E.,
and Morser, J.
(1998)
J. Clin. Invest.
101,
321-326 |
55. |
Kawamura, S.,
Kurachi, S.,
Deyashiki, Y.,
and Kurachi, K.
(1999)
Eur. J. Biochem.
262,
755-764 |
56. |
Yan, W.,
Wu, F.,
Morser, J.,
and Wu, Q.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8525-8529 |
57. | Lang, R. E., Tholken, H., Ganten, D., Luft, F. C., Ruskoaho, H., and Unger, T. (1985) Nature 314, 264-266[Medline] [Order article via Infotrieve] |
58. | Koshelnick, Y., Ehart, M., Stockinger, H., and Binder, B. R. (1999) Thromb. Haemostasis 82, 305-311[Medline] [Order article via Infotrieve] |
59. | Wolfsberg, T. G., Primakoff, P., Myles, D. G., and White, J. M. (1995) J. Cell Biol. 131, 275-278[Medline] [Order article via Infotrieve] |
60. | Wolfsberg, T. G., and White, J. M. (1996) Dev. Biol. 180, 389-401[CrossRef][Medline] [Order article via Infotrieve] |
61. |
Schlondorff, J.,
and Blobel, C. P.
(1999)
J. Cell Sci.
112,
3603-3617 |
62. | Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaitre, V., Tipping, P., Drew, A., Eeckhout, Y., Shapiro, S., Lupu, F., and Collen, D. (1997) Nat. Genet. 17, 439-444[Medline] [Order article via Infotrieve] |
63. | Nagase, H., Enghild, J. J., Suzuki, K., and Salvesen, G. (1990) Biochemistry 29, 5783-5789[Medline] [Order article via Infotrieve] |
64. |
Ramos-DeSimone, N.,
Hahn-Dantona, E.,
Sipley, J.,
Nagase, H.,
French, D. L.,
and Quigley, J. P.
(1999)
J. Biol. Chem.
274,
13066-13076 |
65. | Blasi, F. (1999) Thromb. Haemostasis 82, 298-304[Medline] [Order article via Infotrieve] |
66. | Hattori, M., et al.. (2000) Nature 405, 311-319[CrossRef][Medline] [Order article via Infotrieve] |
67. | Yamada, K., Takabatake, T., and Takeshima, K. (2000) Gene (Amst.) 252, 209-216[CrossRef][Medline] [Order article via Infotrieve] |